复发多发性骨髓瘤患者骨髓多克隆浆细胞的预后意义
该研究纳入174例复发多发性骨髓瘤患者,用7色多参数流式细胞术检测骨髓多克隆浆细胞比例。骨髓多克隆浆细胞<5%者至下次治疗时间9.4个月,≥5%者为13.9个月(P=0.0091);<5%者中位总生存21.4个月,≥5%者未达到(P=0.019)。在109例标危细胞遗传学患者中,<5%者中位总生存28.4个月,≥5%者未达到(P=0.033)。
要点
- 复发多发性骨髓瘤患者骨髓多克隆浆细胞<5%者至下次治疗时间更短(9.4个月 vs 13.9个月,P=0.0091)。
- 骨髓多克隆浆细胞<5%者中位总生存21.4个月,≥5%者未达到(P=0.019)。
- 标危细胞遗传学患者中,多克隆浆细胞<5%者中位总生存28.4个月,≥5%者未达到(P=0.033)。
核心结论
- 骨髓多克隆浆细胞<5%似乎可识别出即使标危细胞遗传学也预后特别差的复发多发性骨髓瘤患者亚组。
研究设计与样本
- 研究纳入174例复发多发性骨髓瘤患者,采用7色多参数流式细胞术检测骨髓多克隆浆细胞。
主要发现
- 骨髓多克隆浆细胞<5%者至下次治疗时间9.4个月,≥5%者为13.9个月(P=0.0091)。
- 骨髓多克隆浆细胞<5%者中位总生存21.4个月,≥5%者中位总生存未达到(P=0.019)。
- 109例标危细胞遗传学患者中,骨髓多克隆浆细胞<5%者中位总生存28.4个月,≥5%者未达到(P=0.033)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prior studies have revealed that the presence of increasing number of polyclonal plasma cells (pPCs) in the bone marrow (BM) are associated with better outcomes in newly diagnosed multiple myeloma (MM) patients. This effect has not been studied in patients with MM at the time of disease relapse. We determined the prognostic value of depletion of pPCs in the BM by 7-color multiparameter flow cytometry in a series of 174 relapsing MM patients. The time to next therapy (TTNT) in those with <5% pPCs was 9.4 months versus 13.9 months in those with ≥5% pPCs (P = .0091). The median overall survival (OS) in those with <5% pPCs was 21.4 months, while the median OS was not reached in those patients with ≥5% pPCs (P = .019). Of the 109 patients with standard risk cytogenetics, the median OS of those with <5% pPCs was 28.4 months, while the median OS was not reached in those with ≥5% pPCs (P = .033). As such, <5% pPCs in the BM appears to have prognostic utility in identifying a subset of relapsing MM patients, even with standard-risk cytogenetics, who have a particularly adverse outcome.
引用
- Ghosh T, Gonsalves WI, Jevremovic D, et al. The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma. Am J Hematol. 2017. PMID: 28568244. doi:10.1002/ajh.24807
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。